
BIO-P026
Tirzepatide
Tirzepatide is a long-acting synthetic peptide agonist of both the GIP and GLP-1 receptors. It is an approved active substance marketed in the EU as Mounjaro for type 2 diabetes and weight-management-related indications, with regulatory information updated by EMA in August 2026.









